Healthcare

A Trio of Healthcare Plays Real Money Pro($)

Here's how I'd trade this biotech fund, Incyte and Immunogen.
Amgen's gain is pure insanity from a stock picker's point of view.
Amid the basket's impressive performance, I'm adding Minerva.
The post-earnings trend says the stock will drop after the report.
What to do when central bankers tell you to cut risk.
A lower price means more value for this high-quality stock.

Take a Yellen Opportunity Real Money Pro($)

There's a great entry point in Celgene at $84.
It is preserving its Copaxone franchise, and the executive changes are good news.
Cheap money and greed from the Allergan bidder's side are strong incentives.
A wave of M&A in the health sector makes sense.

Columnist Conversations

Weyerhaeuser (WY) is seeing further weakness after penetrating the channel support I noted yesterday. It looks...
Blow off highs tend to take place on significant news days. In recent years, the monthly employment report ha...
Market trying to hold on to minor gains as we head into the close. Equities have been in a pretty narrow trad...
Shares near $4 and a buyer paid 50c for nearly 1500 Sep 5 calls to open a new position 25% above spot. Earning...

REAL MONEY'S BEST IDEAS

Columnist Tweets

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.